Iovance Biotherapeutics to Present at Two Upcoming Investor Conferences in March

SAN CARLOS, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. IOVA, a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will present at two investor conferences in March:

• Cowen 38^th Annual Health Care Conference in Boston, MA on Wednesday, March 14, 2018 at 10:40 a.m. ET
• Oppenheimer's 28^th Annual Healthcare Conference in New York, NY on Wednesday, March 21, 2018 at 11:30 a.m. ET  

A live audio webcast of both presentations will be available by visiting the Investors section of Iovance Biotherapeutics' website at http://ir.iovance.com/. A replay of the webcasts will be archived on Iovance Biotherapeutics' website for 30 days following the presentations.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. (the Company) is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using TIL technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck, recurrent, metastatic or persistent cervical cancer and locally advanced or metastatic non-small cell lung cancer. For more information, please visit http://www.iovance.com.

Investor Relations Contact:

Sarah McCabe

Stern Investor Relations, Inc.

212-362-1200

sarah@sternir.com



Media Contact:

Evan Smith

FTI Consulting

212-850-5622

evan.smith@fticonsulting.com